NasdaqGM:TRDABiotechs
Entrada Therapeutics (TRDA) Q1 Revenue Slump Tests High Growth Narratives
Entrada Therapeutics (TRDA) Q1 2026 earnings snapshot
Entrada Therapeutics (TRDA) opened 2026 with Q1 revenue of US$0.9 million and a basic EPS loss of US$0.95, with trailing 12 month revenue at US$5.7 million and trailing EPS at a loss of US$4.00. Over recent quarters the company has seen revenue move from US$37.4 million and EPS of US$0.03 in Q4 2024 to US$20.6 million and EPS of US$0.63 in Q1 2025. This was accompanied by a shift from net income of US$65.6 million over the trailing 12...